Taken together, these studies suggest that CRP may provide guidance in prognosis and treatment of mild‐to‐moderate OSA given that some individuals with the disorder have, or will later develop, cardiometabolic sequelae. This evidence concerns the gene CRP and obstructive sleep apnea syndrome.